ArticleEuropean urology open science2025
Prolonged Prophylactic Ureteral Stent Placement and BK Polyomavirus Infection After Renal Transplantation-A Retrospective Case-control Study.
Article in European urology open science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: BK polyomavirus (BKPyV) poses a significant challenge in kidney transplant (KTX) recipients, potentially leading to BKPyV-associated nephropathy. Prophylactic ureteral stent (UrSt) placement is the standard care following KTX. Emerging data suggest that UrSt may influence the incidence and severity of BKPyV-DNAemia. We hypothesized a dose-dependent relationship between an indwelling UrSt and the risk of BKPyV-DNAemia in KTX recipients. Methods: We included all KTX recipients with detectable BKPyV-DNAemia at the Medical University of Vienna from 2010 to 2021; those without DNAemia served as controls. This nested, retrospective, 1:1 sex- and age-matched case-control study assessed whether UrSt placement and/or its duration was associated with BKPyV. Key findings and limitations: Of 438 KTX recipients, 51.6% of viremic patients had received UrSt, compared with 47% of nonviremic controls. While UrSt placement was not associated with the risk of BKPyV-DNAemia (odds ratio [OR] 1.20, 95% confidence interval [CI] 0.83-1.75), indwelling time of >8 wk was (OR 1.79, 95% CI 1.10-2.93, Conclusions and clinical implications: Prophylactic UrSt placement after KTX does not increase the risk of developing BKPyV-DNAemia. However, the indwelling time of the UrSt should be limited to <8 wk to reduce the risk of BKPyV-DNAemia. Therefore, early removal of UrSt-preferably within 8 wk-should be pursued when clinically feasible. Further research is needed to define the optimal UrSt indwelling time and clarify the underlying pathophysiological mechanisms. Patient summary: In this study, we examined whether the placement and duration of ureteral stents after kidney transplantation affect the risk of developing a BK polyomavirus that can harm the transplanted organ. We found that the length of time the stent remains in place-especially beyond 8 weeks-was linked to a higher risk of viral reactivation. Removal of the stent earlier may help protect patients from these complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.